CN105907719A - Anti ROBO1 CAR-T细胞及其制备和应用 - Google Patents
Anti ROBO1 CAR-T细胞及其制备和应用 Download PDFInfo
- Publication number
- CN105907719A CN105907719A CN201610237593.2A CN201610237593A CN105907719A CN 105907719 A CN105907719 A CN 105907719A CN 201610237593 A CN201610237593 A CN 201610237593A CN 105907719 A CN105907719 A CN 105907719A
- Authority
- CN
- China
- Prior art keywords
- cell
- car
- scfv
- fusion protein
- robo1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 96
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000014509 gene expression Effects 0.000 claims abstract description 9
- 101000650694 Homo sapiens Roundabout homolog 1 Proteins 0.000 claims description 31
- 102100027702 Roundabout homolog 1 Human genes 0.000 claims description 31
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 210000002751 lymph Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 101710135378 pH 6 antigen Proteins 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 206010041047 Slow virus infection Diseases 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract 1
- 108700002783 roundabout Proteins 0.000 abstract 1
- 101150097792 Robo1 gene Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000012636 effector Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003677 hemocyte Anatomy 0.000 description 3
- 229940000351 hemocyte Drugs 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010073364 Ductal adenocarcinoma of pancreas Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610237593.2A CN105907719B (zh) | 2016-04-18 | 2016-04-18 | Anti ROBO1 CAR-T细胞及其制备和应用 |
US16/094,247 US11345893B2 (en) | 2016-04-18 | 2016-07-31 | Anti-ROBO1 CAR-T cell, and preparation and application thereof |
PCT/CN2016/092577 WO2017181552A1 (zh) | 2016-04-18 | 2016-07-31 | Anti ROBO1 CAR-T细胞及其制备和应用 |
US17/732,581 US20220267731A1 (en) | 2016-04-18 | 2022-04-29 | Anti-robo1 car-t cell, and preparation and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610237593.2A CN105907719B (zh) | 2016-04-18 | 2016-04-18 | Anti ROBO1 CAR-T细胞及其制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105907719A true CN105907719A (zh) | 2016-08-31 |
CN105907719B CN105907719B (zh) | 2019-10-18 |
Family
ID=56747251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610237593.2A Active CN105907719B (zh) | 2016-04-18 | 2016-04-18 | Anti ROBO1 CAR-T细胞及其制备和应用 |
Country Status (3)
Country | Link |
---|---|
US (2) | US11345893B2 (zh) |
CN (1) | CN105907719B (zh) |
WO (1) | WO2017181552A1 (zh) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107227299A (zh) * | 2017-06-01 | 2017-10-03 | 刘未斌 | Anti MUC1 CAR‑T细胞及其制备方法和应用 |
CN107987169A (zh) * | 2018-01-05 | 2018-05-04 | 李华顺 | 一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用 |
CN107988164A (zh) * | 2016-10-26 | 2018-05-04 | 阿思科力(苏州)生物科技有限公司 | 一种pd-1 car nk-92细胞及其制备方法与应用 |
WO2018218710A1 (zh) * | 2017-06-02 | 2018-12-06 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用 |
CN109810995A (zh) * | 2017-12-06 | 2019-05-28 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
CN110225770A (zh) * | 2016-12-14 | 2019-09-10 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
CN110592023A (zh) * | 2019-09-11 | 2019-12-20 | 浙江蓝盾药业有限公司 | 一种Anti CD70 CAR-T细胞及其制备方法与应用 |
CN110734931A (zh) * | 2019-11-18 | 2020-01-31 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种靶向CD19的人源化scFv嵌合抗原受体T细胞及制备方法、应用 |
CN110746509A (zh) * | 2019-10-10 | 2020-02-04 | 中国人民解放军第四军医大学 | 一种抗人cd147 car-t细胞、制备方法和应用 |
CN110885790A (zh) * | 2019-10-30 | 2020-03-17 | 武汉大学 | 靶向mmsa-1嵌合抗原受体修饰t淋巴细胞及其制备方法和应用 |
CN111269925A (zh) * | 2019-03-15 | 2020-06-12 | 阿思科力(苏州)生物科技有限公司 | 携带自杀基因的robo1 car-nk细胞及其制备方法和应用 |
US11345739B2 (en) | 2016-12-14 | 2022-05-31 | Janssen Biotech, Inc | CD137 binding fibronectin type III domains |
US11447539B2 (en) | 2016-12-14 | 2022-09-20 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
CN115873133A (zh) * | 2023-01-18 | 2023-03-31 | 汕头普罗凯融生物医药科技有限公司 | 一种用于治疗结肠癌的特异性识别抗原robo1的嵌合抗原受体 |
US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
CN117384290A (zh) * | 2023-12-11 | 2024-01-12 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113373523B (zh) * | 2021-08-02 | 2022-06-28 | 中南大学湘雅医院 | 重症肌无力外周血单细胞转录组文库及制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095895A1 (en) * | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
CN104788573A (zh) * | 2015-05-08 | 2015-07-22 | 中国医学科学院血液病医院(血液学研究所) | 嵌合抗原受体hCD19scFv-CD8α-CD28-CD3ζ及其用途 |
CN105331586A (zh) * | 2015-11-20 | 2016-02-17 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX347078B (es) * | 2010-12-09 | 2017-04-10 | Univ Pennsylvania | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer. |
US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
JP6661544B2 (ja) * | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したt細胞の自動生成法 |
-
2016
- 2016-04-18 CN CN201610237593.2A patent/CN105907719B/zh active Active
- 2016-07-31 US US16/094,247 patent/US11345893B2/en active Active
- 2016-07-31 WO PCT/CN2016/092577 patent/WO2017181552A1/zh active Application Filing
-
2022
- 2022-04-29 US US17/732,581 patent/US20220267731A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095895A1 (en) * | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
CN104788573A (zh) * | 2015-05-08 | 2015-07-22 | 中国医学科学院血液病医院(血液学研究所) | 嵌合抗原受体hCD19scFv-CD8α-CD28-CD3ζ及其用途 |
CN105331586A (zh) * | 2015-11-20 | 2016-02-17 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107988164B (zh) * | 2016-10-26 | 2020-07-07 | 阿思科力(苏州)生物科技有限公司 | 一种pd-1 car nk-92细胞及其制备方法与应用 |
CN107988164A (zh) * | 2016-10-26 | 2018-05-04 | 阿思科力(苏州)生物科技有限公司 | 一种pd-1 car nk-92细胞及其制备方法与应用 |
US11331345B2 (en) | 2016-10-26 | 2022-05-17 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | PD-1 CAR NK-92 cell and preparation method and use thereof |
US11932680B2 (en) | 2016-12-14 | 2024-03-19 | Janssen Biotech, Inc. | CD8A-binding fibronectin type III domains |
CN110225770A (zh) * | 2016-12-14 | 2019-09-10 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
US11447539B2 (en) | 2016-12-14 | 2022-09-20 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
US11345739B2 (en) | 2016-12-14 | 2022-05-31 | Janssen Biotech, Inc | CD137 binding fibronectin type III domains |
US11299534B2 (en) | 2016-12-14 | 2022-04-12 | Janssen Biotech, Inc. | CD8A-binding fibronectin type III domains |
CN107227299A (zh) * | 2017-06-01 | 2017-10-03 | 刘未斌 | Anti MUC1 CAR‑T细胞及其制备方法和应用 |
WO2018218710A1 (zh) * | 2017-06-02 | 2018-12-06 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用 |
CN108977453A (zh) * | 2017-06-02 | 2018-12-11 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用 |
US11697685B2 (en) | 2017-06-02 | 2023-07-11 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | Chimeric antigen receptor cells targeting ROBO1, preparation method and use thereof |
US11738051B2 (en) | 2017-12-06 | 2023-08-29 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | Nucleotide sequences for encoding CAR, ROBO1 CAR-NK cells of expressing the CAR, and preparation and application thereof |
WO2019109838A1 (zh) * | 2017-12-06 | 2019-06-13 | 李华顺 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
CN109810995B (zh) * | 2017-12-06 | 2020-10-02 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
AU2018378395B2 (en) * | 2017-12-06 | 2022-02-03 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | Nucleotide sequence encoding car, ROBO1 CAR-NK cell expressing car and preparation therefor and use thereof |
CN109810995A (zh) * | 2017-12-06 | 2019-05-28 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
CN107987169A (zh) * | 2018-01-05 | 2018-05-04 | 李华顺 | 一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用 |
AU2020243787B2 (en) * | 2019-03-15 | 2023-09-07 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | ROBO1 CAR-NK cell carrying suicide gene, preparation method therefor and application thereof |
CN111269925A (zh) * | 2019-03-15 | 2020-06-12 | 阿思科力(苏州)生物科技有限公司 | 携带自杀基因的robo1 car-nk细胞及其制备方法和应用 |
CN111269925B (zh) * | 2019-03-15 | 2024-01-30 | 阿思科力(苏州)生物科技有限公司 | 携带自杀基因的robo1 car-nk细胞及其制备方法和应用 |
AU2020243787B9 (en) * | 2019-03-15 | 2023-09-28 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | ROBO1 CAR-NK cell carrying suicide gene, preparation method therefor and application thereof |
EP3940076A4 (en) * | 2019-03-15 | 2022-11-16 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | SUICIDE-GEN-CARRYING ROBO1-CAR-NK CELL, METHOD OF ITS MANUFACTURE AND APPLICATION THEREOF |
CN110592023A (zh) * | 2019-09-11 | 2019-12-20 | 浙江蓝盾药业有限公司 | 一种Anti CD70 CAR-T细胞及其制备方法与应用 |
CN110592023B (zh) * | 2019-09-11 | 2020-09-04 | 浙江蓝盾药业有限公司 | 一种Anti CD70 CAR-T细胞及其制备方法与应用 |
CN110746509B (zh) * | 2019-10-10 | 2023-05-02 | 中国人民解放军第四军医大学 | 一种抗人cd147 car-t细胞、制备方法和应用 |
CN110746509A (zh) * | 2019-10-10 | 2020-02-04 | 中国人民解放军第四军医大学 | 一种抗人cd147 car-t细胞、制备方法和应用 |
US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
CN110885790A (zh) * | 2019-10-30 | 2020-03-17 | 武汉大学 | 靶向mmsa-1嵌合抗原受体修饰t淋巴细胞及其制备方法和应用 |
CN110885790B (zh) * | 2019-10-30 | 2021-07-20 | 武汉大学 | 靶向mmsa-1嵌合抗原受体修饰t淋巴细胞及其制备方法和应用 |
CN110734931A (zh) * | 2019-11-18 | 2020-01-31 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种靶向CD19的人源化scFv嵌合抗原受体T细胞及制备方法、应用 |
CN115873133B (zh) * | 2023-01-18 | 2023-09-29 | 汕头普罗凯融生物医药科技有限公司 | 一种用于治疗结肠癌的特异性识别抗原robo1的嵌合抗原受体 |
CN115873133A (zh) * | 2023-01-18 | 2023-03-31 | 汕头普罗凯融生物医药科技有限公司 | 一种用于治疗结肠癌的特异性识别抗原robo1的嵌合抗原受体 |
CN117384290A (zh) * | 2023-12-11 | 2024-01-12 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
CN117384290B (zh) * | 2023-12-11 | 2024-04-09 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US11345893B2 (en) | 2022-05-31 |
US20220267731A1 (en) | 2022-08-25 |
WO2017181552A1 (zh) | 2017-10-26 |
CN105907719B (zh) | 2019-10-18 |
US20190127696A1 (en) | 2019-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105907719A (zh) | Anti ROBO1 CAR-T细胞及其制备和应用 | |
CN106399255B (zh) | Pd-1 car-t细胞及其制备方法和应用 | |
CN104788573B (zh) | 嵌合抗原受体hCD19scFv-CD8α-CD28-CD3ζ及其用途 | |
CN109400713B (zh) | 新型嵌合抗原受体修饰的t细胞治疗癌症的用途 | |
CN107868791B (zh) | 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用 | |
CN109182266A (zh) | 扩大t细胞的方法 | |
CN108752482B (zh) | 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用 | |
WO2020187016A1 (zh) | 携带自杀基因的robo1 car-nk细胞及其制备方法和应用 | |
WO2018058431A1 (zh) | 一种嵌合抗原受体分子及其应用 | |
CN109422815A (zh) | 双特异性嵌合抗原受体c-Met/PD-1 scFv-CAR-T及其构建方法和应用 | |
CN109721659A (zh) | 一种靶向cd19的新型嵌合抗原受体(car)及其应用 | |
CN107298715B (zh) | Slit2D2-嵌合抗原受体及其应用 | |
CN108047333A (zh) | 以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用 | |
CN108285486A (zh) | 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用 | |
CN109666651B (zh) | 一种分泌型靶向Lewis-Y的CAR-T细胞 | |
CN113045675A (zh) | 一种抗cd22蛋白分子的抗体及其应用 | |
CN108314739A (zh) | 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用 | |
WO2018058432A1 (zh) | 一种多基因重组嵌合抗原受体分子及其应用 | |
CN103013906B (zh) | 一种生物膜及其制备方法和应用 | |
CN109970869A (zh) | 一种靶向人trail死亡受体的嵌合受体配体及其应用 | |
CN109232742A (zh) | 一种嵌合抗原受体及其应用 | |
CN108690829A (zh) | 一种高效扩增nk细胞的方法 | |
CN111286512A (zh) | 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途 | |
CN108743617A (zh) | miR-15a-5p在提高CAR-T细胞抗肿瘤能力中的应用 | |
CN109055317A (zh) | 一种AFP与HBsAg双抗原基因修饰的DC联合CIK免疫细胞及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190521 Address after: Room A2-427, 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province Applicant after: ASCO (Suzhou) Biotechnology Co., Ltd. Address before: 100000 No. 25 Taiping Road, Haidian District, Beijing Applicant before: Li Huashun |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210512 Address after: No.129-8, Jiannan Road, Jinniu District, Chengdu, Sichuan 610081 Patentee after: Sichuan asikeli Biotechnology Co.,Ltd. Address before: Room A2-427, 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province Patentee before: ASCLEPIUS (Suzhou) TECHNOLOGY COMPANY GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right |